SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ANSS, HRT, CHX, ABIO

NEW YORK, April 10, 2024

ANSYS, Inc. (NASDAQ: ANSS)'s sale to Synopsys, Inc. for $197.00 in cash and 0.3450 shares of Synopsys common stock for each ANSYS share. Under the terms of the agreement, ANSYS shareholders are expected to own approximately 16.5% of the combined company on a pro forma basis. If you are an ANSYS shareholder, click here to learn more about your rights and options.

HireRight Holdings Corporation (NYSE: HRT)'s sale to affiliates of General Atlantic, L.P. and Stone Point Capital LLC for $14.35 per share in cash. If you are a HireRight shareholder, click here to learn more about your rights and options.

ChampionX Corporation (NASDAQ: CHX)'s sale to SLB for 0.735 shares of SLB common stock in exchange for each ChampionX share. Upon closing of the proposed transaction, ChampionX shareholders will own approximately 9% of SLB's outstanding shares of common stock. If you are a ChampionX shareholder, click here to learn more about your rights and options.

ARCA biopharma, Inc. (NASDAQ: ABIO)'s merger with Oruka Therapeutics. Upon closing of the proposed transaction, ARCA shareholders are expected to own approximately 2.38% of the combined company. If you are an ARCA shareholder, click here to learn more about your rights and options.

Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders. We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.